US › Healthcare

FibroBiologics, Inc. Common Stock (FBLG)

US · Healthcare · Biotechnology

$0.98+2.39%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.1M

EPS

$-0.66

EPS estimate

$-0.93

EPS came in at -0.66 against a street estimate of -0.93 — a beat of 29.0%.

Key statistics

Market cap

$6.8M

Forward P/E

0.0

P/B

1.50

Book value

$0.76

EPS (TTM)

$-5.01

52-week high

$9.60

52-week low

$0.62

50-day MA

$1.28

200-day MA

$2.29

Beta

1.84

Analyst view

Analysts rate FibroBiologics, Inc. Common Stock a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $12.50.

Shareholding

Insiders

13.74%

Institutions

15.25%

Largest institutional holders

Fund	Stake
Fund Evaluation Group, LLC	0.73%
Geode Capital Management, LLC	0.43%
Vanguard Capital Management, LLC	0.39%
Qube Research & Technologies	0.34%
BlackRock Inc	0.26%
Barclays PLC	0.10%
Vanguard Fiduciary Trust Co	0.09%
Tower Research Capital LLC	0.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for FibroBiologics, Inc. Common Stock — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.